LAMP-1 Chimeric to HIV-1 p55Gag in the Immunization of Neonate Mice Induces an Early Germinal Center Formation and AID Expression

Imagem de Miniatura
Arquivos
art_TEIXEIRA_LAMP1_Chimeric_to_HIV1_p55Gag_in_the_Immunization_2022.PDF (1.63 MB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
SALLES, Erika Machado de
LIMA, Maria Regina D'Imperio
VIANA, Isabelle Freire Tabosa
LINS, Roberto Dias
RIGATO, Paula Ordonhez
MARQUES, Ernesto Torres de Azevedo
Citação
VACCINES, v.10, n.8, article ID 1246, 14p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Neonates have a limited adaptive response of plasma cells, germinal center (GC) B cells, and T follicular helper cells (T-FH). As neonatal vaccination can be an important tool for AIDS prevention, these limitations need to be overcome. Chimeric DNA vaccine encoding p55Gag HIV-1 protein conjugated with lysosomal-associated membrane protein 1 (LAMP-1) has been described as immunogenic in the neonate period. Herein, we investigated the immunologic mechanisms involved in neonatal immunization with a LAMP-1/p55Gag (LAMP/Gag) DNA vaccine in a C57BL/6 mouse background. Neonatal LAMP/Gag vaccination induced strong Gag-specific T-cell response until adulthood and elevated levels of anti-Gag IgG antibodies. We also demonstrated for the first time that the immunogenicity of the neonatal period with LAMP/Gag is due to the induction of high-affinity anti-p24 IgG antibodies and long-term plasma cells. Together with that, there is the generation of early TFH cells and the formation of GC sites with the upregulation of activation-induced cytidine deaminase (AID) enzyme mRNA and protein expression in draining lymph nodes after neonatal LAMP/Gag vaccination. These findings underscore that the LAMP-1 strategy in the chimeric vaccine could be useful to enhance antibody production even in the face of neonatal immaturity, and they contribute to the development of new vaccine approaches for other emerging pathogens at an early stage of life.
Palavras-chave
DNA vaccine, neonate, HIV, immunogenicity, germinal center
URI
https://observatorio.fm.usp.br/handle/OPI/49357
Referências
  1. Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003
  2. [Anonymous], GLOB HIV AIDS STAT F
  3. Arruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265
  4. Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
  5. BUSEYNE F, 1994, CLIN EXP IMMUNOL, V97, P353
  6. Capozzo AVE, 2006, J IMMUNOL, V176, P5671, DOI 10.4049/jimmunol.176.9.5671
  7. Chikhlikar P, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000135
  8. Chung AW, 2018, AIDS, V32, P1207, DOI 10.1097/QAD.0000000000001812
  9. Cinicola B, 2021, FRONT PEDIATR, V9, DOI 10.3389/fped.2021.638871
  10. De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
  11. de Brito CA, 2009, IMMUNOTHERAPY-UK, V1, P883, DOI 10.2217/IMT.09.38
  12. Debock I, 2013, J IMMUNOL, V191, P1231, DOI 10.4049/jimmunol.1203288
  13. Duerr A, 2012, J INFECT DIS, V206, P258, DOI 10.1093/infdis/jis342
  14. Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404
  15. Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399
  16. Gavillet BM, 2015, J IMMUNOL, V194, P4836, DOI 10.4049/jimmunol.1402071
  17. Goenka A, 2015, J INFECTION, V71, pS112, DOI 10.1016/j.jinf.2015.04.027
  18. Goldoni AL, 2011, IMMUNOBIOLOGY, V216, P505, DOI 10.1016/j.imbio.2010.08.007
  19. Goodnow CC, 2010, NAT IMMUNOL, V11, P681, DOI 10.1038/ni.1900
  20. Gray GE, 2011, LANCET INFECT DIS, V11, P507, DOI 10.1016/S1473-3099(11)70098-6
  21. Hassett DE, 2000, J VIROL, V74, P2620, DOI 10.1128/JVI.74.6.2620-2627.2000
  22. Herath S, 2016, VACCINE, V34, P4378, DOI 10.1016/j.vaccine.2016.07.028
  23. Jain S., 2021, BIORXIV, DOI [10.1101/2021.06.16.448593, DOI 10.1101/2021.06.16.448593]
  24. Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870
  25. Kaushik S, 2005, CLIN EXP IMMUNOL, V142, P388, DOI 10.1111/j.1365-2249.2005.02926.x
  26. Keim C, 2013, GENE DEV, V27, P1, DOI 10.1101/gad.200014.112
  27. KLEIJMEER MJ, 1995, J IMMUNOL, V154, P5715
  28. Kollmann TR, 2017, IMMUNITY, V46, P350, DOI 10.1016/j.immuni.2017.03.009
  29. Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432
  30. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  31. Loeffler FF, 2021, RSC MED CHEM, V12, P1525, DOI 10.1039/d1md00124h
  32. Lofano G, 2015, J IMMUNOL, V195, P1617, DOI 10.4049/jimmunol.1402604
  33. Ma CS, 2012, J EXP MED, V209, P1241, DOI 10.1084/jem.20120994
  34. Maciel M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003693
  35. Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
  36. Mastelic B, 2012, J IMMUNOL, V189, P5764, DOI 10.4049/jimmunol.1201143
  37. Mata M, 1998, J IMMUNOL, V161, P2985
  38. Munguia-Fuentes R, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00013
  39. Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7
  40. Norris PJ, 2004, AIDS RES HUM RETROV, V20, P315, DOI 10.1089/088922204322996554
  41. Oliveira LMS, 2015, SCI REP-UK, V5, DOI 10.1038/srep13883
  42. Petrovas C, 2012, J CLIN INVEST, V122, P3281, DOI 10.1172/JCI63039
  43. Pihlgren M, 2003, J IMMUNOL, V170, P2824, DOI 10.4049/jimmunol.170.6.2824
  44. Pind AAA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02214
  45. Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748
  46. Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
  47. Rigato PO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031608
  48. Rigato PO, 2010, VIROLOGY, V406, P37, DOI 10.1016/j.virol.2010.06.050
  49. Rolland M, 2012, NATURE, V490, P417, DOI 10.1038/nature11519
  50. Ruff AL, 1997, J BIOL CHEM, V272, P8671, DOI 10.1074/jbc.272.13.8671
  51. Schussek S, 2020, MUCOSAL IMMUNOL, V13, P545, DOI 10.1038/s41385-020-0253-2
  52. Sedegah M, 2003, J IMMUNOL, V171, P3148, DOI 10.4049/jimmunol.171.6.3148
  53. Vono M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00381
  54. Wu L, 2005, J VIROL, V79, P8024, DOI 10.1128/JVI.79.13.8024-8031.2005
  55. Yu XG, 2002, AIDS, V16, P321, DOI 10.1097/00002030-200202150-00002

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/56
Artigos e Materiais de Revistas Científicas - ODS/03
Artigos e Materiais de Revistas Científicas - ODS/05